Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM), in combination with fulvestrant (FUL), are approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. This study aims to determine relative efficacy of PAL+FUL versus RIB+FUL and ABM+FUL using matching-adjusted indirect treatment comparisons. Patients & methods: Anchored matching-adjusted indirect treatment comparisons were conducted using individual patient data from PALOMA-3 and published summary-level data from MONARCH 2 and MONALEESA-3. The primary outcome was overall survival (OS). Results: OS was similar for PAL+FUL versus ABM+FUL (hazard ratio: 0.87; 95% CI: 0.54–1.40) and RIB+FUL (hazard ratio: 0.89; 95% CI: 0.48–1.63). Conclusion: Adjusting for cross-trial differences suggests similar OS between treatments, underscoring the importance of accounting for these differences when indirectly comparing treatments.
Lay abstract
Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are used with fulvestrant to treat hormone receptor-positive, HER2-negative advanced breast cancer. This study aims to use data from clinical trials to compare how long patients live after starting treatment with PAL versus RIB and ABM. Since patients who enroll in different trials may have different characteristics, it is important to adjust for these differences for a more accurate comparison. Adjusting for these differences showed that patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with PAL lived for a similar length of time compared with those treated with RIB or ABM.
Supplementary Material
File (suppl_data.zip)
- Download
- 1.51 MB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
2.
Ferlay J, Colombet M, Soerjomataram I et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144(8), 1941–1953 (2019).
3.
National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: female breast cancer (2020). https://seer.cancer.gov/statfacts/html/breast-subtypes.html
4.
Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle 17(15), 1871–1885 (2018).
5.
Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18(1), 17 (2016).
6.
Xu H, Yu S, Liu Q et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J. Hematol. Oncol. 10(1), 97 (2017).
7.
United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - palbociclib (IBRANCE) (2020). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207103
8.
Turner NC, Ro J, André F et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N. Engl. J. Med. 373(3), 209–219 (2015).
• Presents the primary outcome and baseline characteristics of the Phase III PALOMA-3 clinical trial.
9.
United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - ribociclib (KISQALI) (2020). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209092
10.
Slamon DJ, Neven P, Chia S et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36(24), 2465–2472 (2018).
• Outlines the primary outcome and baseline characteristics of the Phase III MONALEESA-3 clinical trial.
11.
United States Food & Drug Administration. Drugs@FDA: FDA-approved drugs - abemaciclib (VERZENIO) (2020). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208716
12.
Sledge GW, Toi M, Neven P et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35(25), 2875–2884 (2017).
• Presents the primary outcome and baseline characteristics of the Phase III MONARCH 2 clinical trial.
13.
Petrelli F, Ghidini A, Pedersini R et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res. Treat. 174(3), 597–604 (2019).
14.
Turner NC, Slamon DJ, Ro J et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379(20), 1926–1936 (2018).
• Highlights overall survival (OS) results from the Phase III PALOMA-3 clinical trial.
15.
Sledge GW, Toi M, Neven P et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: a randomized clinical trial. JAMA Oncol. 6(1), 116–124 (2019).
•• Describes OS results from the Phase III MONARCH 2 clinical trial.
16.
Slamon DJ, Neven P, Chia S et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382(6), 514–524 (2019).
•• Describes OS results from the Phase III MONALEESA-3 clinical trial.
17.
National Institute for Health and Care Excellence. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE (2020). http://nicedsu.org.uk/wp-content/uploads/2018/08/Population-adjustment-TSD-FINAL-ref-rerun.pdf
•• Outlines recommendations on the methods for and use of matching-adjusted indirect comparisons.
18.
Bellet M, Ahmad F, Villanueva R et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther. Adv. Med. Oncol. 11, 1–43 (2019).
19.
Zhang T, Feng F, Zhao W et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. Cancer Manag. Res. 10, 5869 (2018).
20.
Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M. Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer. Cancer Manag. Res. 10, 1319 (2018).
Information & Authors
Information
Published In
Pages: 457 - 467
PubMed: 33626934
Copyright
© 2021 Hope S Rugo. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 8 December 2020
Accepted: 27 January 2021
Published online: 25 February 2021
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0272
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- K. Jhaveri, F.C. Bidard, K. Kalinsky, P. Neven, H.S. Rugo, S.M. Tolaney, L.M. Litchfield, C.C. von Laue, S. Traore, F. Sapunar, Y. Li, J. O’Shaughnessy, Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials, ESMO Open, 10.1016/j.esmoop.2026.106091, 11, 3, (106091), (2026).
- Seda Kahraman, Enes Erul, Ozge Gumusay, Deniz Can Guven, Sercan Aksoy, Gul Basaran, Mustafa Seyyar, Elif Sahin, Devrim Cabuk, Ertugrul Bayram, Semra Paydas, Burcin Cakan Demirel, Arzu Yaren, Burcu Gulbagci, Ilhan Hacibekiroglu, Naziyet Kose Baytemur, Umut Demirci, Sena Ece Davarci, Hacer Demir, Eda Eylemer Mocan, Ozlem Dogan, Ebru Cilbir, Alper Yasar, Ibrahim Vedat Bayoglu, Mutlu Hizal, Erkan Kayikcioglu, Bulent Cetin, Omer Acar, Atike Pinar Erdogan, Merve Keskinkilic, Tugba Yavuzsen, Olcun Umit Unal, Funda Yilmaz, Mutlu Dogan, Sibel Oyucu Orhan, Erdem Cubukcu, Cihan Erol, Teoman Sakalar, Ozgecan Dulgar, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Deniz Isik, Muge Karaoglanoglu, Sadi Kerem Okutur, Nilgun Yildirim, Esra Aydin, Basak Oyan Uluc, Murat Keser, Burak Bilgin, Asude Aksoy, Onder Eren, Nurhan Onal Kalkan, Muhammed Muhiddin Er, Hakan Yucel, Veli Sunar, Nail Paksoy, Dincer Aydin, Nazim Serdar Turhal, Serkan Menekse, Engin Kut, Musa Baris Aykan, Ozlem Ozdemir, Melike Ozcelik, Yakup Iriagac, Fatih Selcukbiricik, Ali Inal, Nuri Karadurmus, Muhammed Bulent Akinci, Mehmet Ali Nahit Sendur, Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study, Clinical Breast Cancer, 10.1016/j.clbc.2025.03.003, 25, 5, (e635-e644), (2025).
- Cecília Menezes Farinasso, Vinícius Lins Ferreira, Flávia Cordeiro Medeiros, Aline Pereira da Rocha, Patrícia do Carmo Silva Parreira, Layssa Andrade Oliveira, Lays Pires Marra, Rosa Camila Lucchetta, Haliton Alves de Oliveira, Matching-Adjusted Indirect Comparison Studies in Oncology: A Scoping Review Focused on Reporting Quality, Value in Health Regional Issues, 10.1016/j.vhri.2025.101088, 47, (101088), (2025).
- Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari, Alexander Niyazov, Imtiaz A. Samjoo, Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC, Future Oncology, 10.1080/14796694.2025.2471200, 21, 9, (1075-1084), (2025).
- Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari, Alexander Niyazov, Imtiaz A. Samjoo, Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison, Prostate Cancer and Prostatic Diseases, 10.1038/s41391-024-00924-x, 28, 3, (817-827), (2024).
- Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda, Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer, Scientific Reports, 10.1038/s41598-024-60101-x, 14, 1, (2024).
- Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo, Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer , Therapeutic Advances in Medical Oncology, 10.1177/17588359231216095, 15, (2023).
- Arnaud Serret-Larmande, Belkacem Zenati, Agnès Dechartres, Jérôme Lambert, David Hajage, A methodological review of population-adjusted indirect comparisons reveals inconsistent reporting and suggests publication bias, Journal of Clinical Epidemiology, 10.1016/j.jclinepi.2023.09.004, 163, (1-10), (2023).
- Tanju Kapagan, Nilufer Bulut, Serhat Demirer, Gokmen Umut Erdem, Ribociclib-induced visual hallucination in a patient with metastatic breast cancer, Journal of Oncology Pharmacy Practice, 10.1177/10781552231180463, 29, 6, (1529-1532), (2023).
- Ernest H Law, Chris Cameron, Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant, Journal of Comparative Effectiveness Research, 10.57264/cer-2023-0009, 12, 6, (2023).